企業を読み込み中
Just reported
Q3 2026 results
From AbbVie's results release of 2026年10月30日; its quarterly report has since been filed.
Revenue
Actual
$17.4B
+10% y/y
+2.4% q/qGuided
—
No guide given
EPS, GAAP
Actual
$2.37
+17% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$6.27B
+229% y/y
-2.6% q/qGuided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes AbbVie is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company$1.35TA+
JNJJohnson & Johnson$682.6BA+
MRKMerck & Co., Inc.$362.2BA
NVSNovartis AG$305.8BA
AMGNAmgen Inc.$252.6BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
どうやって稼いでいるか
- Sales of medicines and therapies100%
売上構成比はfiscal year 2025, high confidenceの推計であり、提出された報告書の数字ではありません。
競合
何を売っているか6
Skyrizi
An injectable biologic medicine for autoimmune diseases including psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In 2026, U.S. and European regulators also approved it for some children with plaque psoriasis.
Rinvoq
A once-daily pill for several inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease. European regulators approved it for vitiligo and severe alopecia areata in 2026.
Humira
An injectable biologic medicine used for autoimmune conditions including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. It faces competition from biosimilar medicines.
さらに3件を表示
Botox Therapeutic and Botox Cosmetic
An injectable medicine used therapeutically for conditions including chronic migraine and muscle disorders; its cosmetic version temporarily reduces the appearance of facial lines.
Vraylar
A prescription medicine used to treat schizophrenia and episodes of bipolar disorder, and alongside other medicine for major depression.
Venclexta
A cancer medicine used for blood cancers including chronic lymphocytic leukemia and acute myeloid leukemia. In 2026, U.S. regulators approved a combination with another cancer medicine for some previously untreated adults with chronic lymphocytic leukemia.
誰が買っているか5
- Wholesalers and distributors buy medicines for resale to pharmacies, hospitals and other healthcare providers.
- Government agencies and public health programs buy medicines or set coverage and reimbursement terms.
- Health insurers and pharmacy benefit managers influence which medicines patients can access and the prices or rebates paid.
さらに2件を表示
- Hospitals, health facilities, specialty pharmacies and independent pharmacies buy medicines for use or dispensing to patients.
- Physicians and other licensed healthcare providers prescribe AbbVie's prescription medicines and can buy some aesthetic products and devices directly.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1AbbVie relies on large wholesale distributors to move its medicines, especially in the United States.
- 2Some medicines or manufacturing components depend on a limited number of suppliers, and in some cases a single supply source.
- 3Revenue depends on patents and regulatory exclusivity; Humira already faces biosimilar competition.
- 4Pricing and patient access depend partly on government reimbursement rules, insurers and pharmacy benefit managers.
- 5The business depends on discovering, testing and obtaining regulatory approval for new medicines, including products developed with collaborators.
うまくいかなくなる可能性
- 1Patent expirations and biosimilar or generic competition can reduce sales. Humira's sales continued to fall amid biosimilar competition in the six months ended June 30, 2026.
- 2Government price controls, reimbursement limits and pressure from insurers and pharmacy benefit managers can reduce the prices AbbVie receives for its medicines.
- 3Research and development may not produce medicines that pass clinical trials and regulatory review or attract enough use after approval, leaving gaps as existing products lose exclusivity.
AbbVie Inc.について
AbbVie researches, tests, makes and sells prescription medicines and some medical devices. Its medicines treat immune diseases, neurological conditions, cancers, migraine, eye diseases and other conditions; it also sells cosmetic injections, fillers and skincare products. It sells mainly through wholesalers and distributors, with some aesthetic products sold directly to licensed health professionals.
- 本社
- North Chicago, Illinois, United States
- 設立
- 2012 (incorporated; began independent public trading in 2013)
- 従業員数
- Approximately 57,000 (December 31, 2025, high confidence)
- 上場市場
- New York Stock Exchange
- 決算期
- December 31
AbbVie Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。